

# Efficacy of Quetiapine in Parkinson's Psychosis

<b>Submission date</b> 14/07/2005	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered
<b>Registration date</b> 09/09/2005	<b>Overall study status</b> Completed	<input type="checkbox"/> Protocol
<b>Last Edited</b> 06/10/2009	<b>Condition category</b> Nervous System Diseases	<input type="checkbox"/> Statistical analysis plan
		<input checked="" type="checkbox"/> Results
		<input type="checkbox"/> Individual participant data

## Plain English summary of protocol

Not provided at time of registration

## Contact information

### Type(s)

Scientific

### Contact name

Prof Anthony David

### Contact details

Institute of Psychiatry  
P.O. Box 68  
De Crespigny Park  
Denmark Hill  
London  
United Kingdom  
SE5 8AF  
+44 (0)207 848 0138  
A.David@iop.kcl.ac.uk

## Additional identifiers

### Protocol serial number

KCL/KCH-CT2004-1

## Study information

### Scientific Title

### Acronym

EQuiPP

**Study objectives**

The study hypothesis is that Quetiapine is effective in the treatment of the psychotic symptoms (hallucinations/delusions) seen in Parkinson's disease

**Ethics approval required**

Old ethics approval format

**Ethics approval(s)**

Not provided at time of registration

**Study design**

Randomised placebo controlled trial

**Primary study design**

Interventional

**Study type(s)**

Treatment

**Health condition(s) or problem(s) studied**

Parkinson's disease

**Interventions**

Quetiapine versus Placebo

**Intervention Type**

Drug

**Phase**

Not Specified

**Drug/device/biological/vaccine name(s)**

Quetiapine

**Primary outcome(s)**

1. Improvement in psychotic symptoms
2. Parkinsonian symptoms
3. Depressive symptoms
4. Remaining in the trial for the 12 week duration (patients will be withdrawn if their psychotic symptoms worsen)

**Key secondary outcome(s)**

1. Activities of daily living
2. Cognitive function
3. Carer burden

**Completion date**

01/08/2006

# Eligibility

## Key inclusion criteria

1. Hallucinations, delusions of a severity >3/7 on the Brief Psychiatric Rating Scale, 2. Diagnosis of Parkinson's which meets UKPD Society Brain Bank criteria

## Participant type(s)

Patient

## Healthy volunteers allowed

No

## Age group

Adult

## Sex

All

## Key exclusion criteria

1. Anti-psychotic medication in the preceding 3 months
2. Any contra-indication to quetiapine
3. Any important drug interactions
4. Major concomitant medical illness
5. History of uncontrolled diabetes or hypertension
6. Changes in medication in the last 14 days

## Date of first enrolment

01/08/2005

## Date of final enrolment

01/08/2006

# Locations

## Countries of recruitment

United Kingdom

England

## Study participating centre

Institute of Psychiatry

London

United Kingdom

SE5 8AF

# Sponsor information

**Organisation**

King's College London (UK)

**ROR**

<https://ror.org/0220mzb33>

**Funder(s)****Funder type**

Charity

**Funder Name**

Parkinson's Disease Society (UK) (Ref: 4052)

**Results and Publications****Individual participant data (IPD) sharing plan****IPD sharing plan summary**

Not provided at time of registration

**Study outputs**

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Results article</a>	results	01/10/2009		Yes	No